Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial-Reference-Cited by-同舟云学术

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial

Published:2016-11 Issue:5 Volume:70 Page:760-766
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Godtman Rebecka Arnsrud,Holmberg Erik,Khatami Ali,Pihl Carl-Gustaf,Stranne Johan,Hugosson Jonas

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Trends in management for patients with localized prostate cancer, 1990-2013;Cooperberg;JAMA,2015

2. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer;Loeb;J Urol,2013

3. The National Board of Health and Welfare, Sweden. Nationella riktlinjer för bröst-, prostata-, tjocktarms- och ändtarmscancervård 2014. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19383/2014-4-2.pdf

4. Mottet N, Bellmunt J, Briers E, et al. EAU Guidelines on prostate cancer. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf

5. Prostate cancer, version 2.2014;Mohler;J Natl Compr Canc Netw,2014

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable‐risk prostate cancer;Cancer;2024-01-27

2. The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol;BMC Urology;2023-12-11

3. Survival After Cryotherapy Versus Radiotherapy in Low and Intermediate Risk Localized Prostate Cancer;Clinical Genitourinary Cancer;2023-12

4. Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients;Journal of Cancer Research and Clinical Oncology;2023-11-18

5. Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer;BMC Urology;2023-09-30